ECT for Severe Depression: Benefits, Risks, and Clinical Use
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
Electroconvulsive therapy (ECT) is a medical treatment for severe depression that uses a brief electrical stimulus to trigger a controlled seizure under general anesthesia. Modern ECT can provide substantial relief when an episode is life-threatening, includes psychotic or catatonic features, or has not improved with appropriate previous treatments. Its clinical value must be weighed against anesthesia and medical risks, temporary confusion, and possible lasting gaps in autobiographical memory. NICE depression guideline; NIMH brain stimulation guidance.
This guide explains when ECT is recommended, what actually happens in a treatment session, how quickly it may work, what research tells us about outcomes and memory, who should be involved in consent, and how to prevent relapse afterward. It is written for patients, families, and professionals seeking an evidence-based explanation of ECT for depression. Eligibility and treatment settings require an individualized specialist examination.
I. What Is ECT?
Electroconvulsive therapy is a brain stimulation procedure in which electrodes placed on the scalp deliver a brief, carefully controlled electrical current. The induced seizure is monitored, and medication renders the patient unconscious and relaxes the muscles. ECT is typically administered in a hospital or specialist outpatient facility by a coordinated psychiatric and anesthesia team. It does not involve a surgically implanted device. NIMH.
Contemporary procedures use pre-anesthesia assessment, oxygenation, physiological monitoring, short-acting anesthesia, muscle relaxation, controlled stimulus dose, and supervised recovery. Electrode positioning, pulse duration, and stimulus strength can be modified in response to symptom improvement and cognitive effects. The procedure therefore has important technical variations rather than a single universal protocol.
Why a therapeutic seizure?
ECT has repeatedly demonstrated antidepressant efficacy in severe episodes. Its precise biological mechanism is not fully established: hypotheses and research address effects on neural networks, neuroplasticity, and neurochemical signaling. A visible seizure is neither a measurement of future clinical benefit nor proof of structural brain injury. The objective is sustained improvement in clinically important symptoms and functioning, not simply induction of seizure activity. NIMH.
The diagnostic meaning of severe depression
Depressed mood is a symptom; a major depressive episode is a defined clinical syndrome; major depressive disorder is a diagnosis established by the history of episodes and appropriate exclusions. Severity combines symptoms, risk and functional impairment. A screening result, including a high questionnaire score, does not itself determine the diagnosis or the indication for ECT. For the broader diagnostic route, see clinical evaluation of depression.
A major depressive episode can also occur in bipolar I or II disorder. The clinical team must ask about previous hypomania, mania, mixed symptoms, unusually decreased need for sleep, and treatment-associated activation before designing long-term care. ECT has separate indications in some bipolar presentations, but this article focuses on its use for unipolar severe depression.
II. When Is ECT Recommended?
The NICE NG222 guideline recommends considering ECT for severe depression when the patient prefers it because of past response, when rapid improvement is needed because the illness is life-threatening, or when other treatments have been unsuccessful. The VA/DoD major depressive disorder guideline recommends offering ECT for severe major depressive disorder in several specified circumstances, including catatonia, psychotic depression, severe suicidality, need for rapid response, prior favorable response, or inadequate response or intolerability after multiple antidepressants.
Severe depression with urgent medical consequences
Some episodes prevent a person from eating, drinking, moving normally, maintaining hygiene or responding to the environment. Dehydration, malnutrition, severe functional deterioration or catatonia can require urgent inpatient evaluation. When weeks of waiting would add substantial medical danger, ECT may be proposed early. Medical urgency and the patient's condition, rather than a score or a generic treatment algorithm, determine the clinical timing. NICE; VA/DoD.
Psychotic features
A severe depressive episode may involve delusions or hallucinations, sometimes focused on guilt, poverty, bodily catastrophe or deserved punishment. These symptoms change the differential diagnosis, immediate risk assessment and treatment plan. ECT is an established option in severe psychotic depression, especially when rapid or definitive intervention is needed. A full account of psychotic depression belongs to a separate condition-specific discussion. VA/DoD.
Catatonia
Catatonia involves marked changes in motor function, responsiveness and behavior. Mutism, immobility, posturing, or severe agitation can occur; catatonia is associated with more than one psychiatric or medical condition. It requires urgent medical and psychiatric assessment. ECT is among the established treatments when catatonia occurs with severe depressive illness, particularly when danger is substantial. VA/DoD.
Inadequate benefit from previous treatment
When depression persists despite adequate treatment trials, clinicians revisit diagnosis, medication duration and dose, adherence, psychotherapy availability, intolerable effects, physical illness, and co-occurring disorders. Treatment resistance describes a clinically evaluated course rather than a personality trait. The proposed companion article on treatment-resistant depression is a distinct treatment-selection topic; this page centers on ECT itself. A prior unsuccessful treatment history can justify considering ECT, while a life-threatening presentation may justify discussing it earlier.
Previous response and informed preference
A person who benefited substantially from ECT in an earlier episode may choose it again. Another person may prioritize avoiding anesthesia or potential loss of personal memories, even if the acute response could be substantial. Both preferences are clinically relevant. Past experience is an important input, but a previous response cannot guarantee a new response. NICE 1.13.1–1.13.3.
III. How Well Does ECT Work for Severe Depression?
ECT is among the best-established acute interventions for severe depressive episodes. Its effectiveness is documented across decades of research and clinical practice, but response rates differ widely between study populations, methods and endpoints. The population receiving right-unilateral ultrabrief treatment is not identical to one receiving bilateral brief-pulse treatment, and depression with psychosis differs from nonpsychotic treatment-resistant depression. A single headline 'success rate' erases these distinctions. NIMH.
Response, remission and recovery
Response generally means a prespecified substantial decrease in depressive symptom scores. Remission means symptoms have fallen below a study-defined threshold. Recovery reflects sustained improvement, while relapse is a return of symptoms after initial improvement and recurrence is a later new episode. Studies sometimes use slightly different definitions and follow-up periods. A patient may show meaningful functional improvement without meeting formal remission criteria, or meet acute remission criteria and later experience relapse.
How fast can ECT work?
ECT can improve severe depression faster than treatments whose benefits build gradually over several weeks. A standard acute course often comprises six to twelve treatments, commonly three times each week, although the exact number varies by response, clinical urgency and tolerability. Some patients improve after early sessions and others require more sessions or do not achieve adequate benefit. Speed is a clinical advantage in carefully selected emergencies, but it is never a guarantee of immediate remission. NIMH.
The importance of electrode placement and pulse width
Brief-pulse and ultrabrief-pulse ECT use different stimulus durations. Common placements include right unilateral, bitemporal and bifrontal. The combination of placement, pulse width and the dose relative to seizure threshold influences antidepressant effectiveness and cognitive outcomes. Research on cognitive-sparing approaches must therefore report exactly which method was studied. Sackeim et al., technique trial.
A systematic review by Jelovac and McLoughlin, published online in 2025 and in print in 2026, included 30 studies of ultrabrief-pulse ECT. For high-dose ultrabrief right-unilateral treatment, the pooled remission rate was 32.2% and response was 45.3%; switching to another ECT technique occurred in about 28.1% because of perceived inadequate benefit. These are estimates for a particular technique, not general ECT response rates. The authors questioned whether its efficacy should be assumed equivalent to conventional brief-pulse treatment. Molecular Psychiatry meta-analysis.
Why different ECT comparisons may disagree
Treatment comparisons are strongly affected by diagnostic exclusions, previous medication failures, technique, severity, trial duration and whether outcomes are rated by the patient or clinician. For example, a 2023 meta-analysis of five relatively small randomized trials suggested ECT advantages over ketamine for some response and remission outcomes, but emphasized sample size and risk-of-bias limitations. A separate larger trial produced a different result in a narrower patient population. Menon et al., JAMA Psychiatry.
IV. Preparing for an ECT Course
Psychiatric assessment
Preparation begins with a detailed examination of the current episode and previous course. The psychiatrist assesses severity and functional impairment, psychosis, catatonia, suicidal thoughts and behavior, sleep and appetite changes, past mania or hypomania, medication history, co-occurring disorders, previous treatment benefit, and the patient's priorities. Screening questionnaires can document progress but cannot replace diagnostic interviewing. NICE.
Medical and anesthesia assessment
ECT has physiological effects during the seizure and involves general anesthesia. The team reviews cardiovascular and respiratory health, neurological history, prior anesthesia reactions, relevant medication exposures and any other medical conditions. Tests and consultations are individualized. Some medications change seizure threshold, cardiovascular response or anesthetic requirements, so patients should present a complete medication and substance list. Medication should never be independently stopped or adjusted in preparation for ECT.
The team should document physical status, ability to consent, baseline cognitive function, an expected course plan, recovery arrangements, and how complications will be addressed. The risk associated with delaying treatment should be evaluated alongside procedure-related risks. NICE 1.13.2.
Establishing a cognitive baseline
Memory complaints may already exist in severe depression, and some patients have unrelated cognitive difficulties. Before treatment, it is useful to document orientation, attention, capacity for new learning, and significant memories or autobiographical functioning when feasible. A baseline permits more meaningful comparison as the course progresses. Repeated evaluation should include the person's own account of changes in daily life, not only a test score.
V. What Happens During an ECT Session?
Arrival, anesthesia and monitoring
The patient follows individualized fasting and preparation instructions. On arrival, staff confirm identity, clinical status, relevant changes and consent. Intravenous access is established, monitoring is applied and anesthesia is administered by qualified professionals. Oxygenation and cardiovascular function are monitored during treatment and recovery. A muscle relaxant limits the body's physical movements during the induced seizure. NIMH.
The stimulus and monitored seizure
A psychiatrist places scalp electrodes using the selected configuration. A brief stimulus triggers seizure activity under anesthesia, which is monitored rather than inferred from outward movement. The electrical stimulus and seizure represent only part of the appointment; preparation and recovery make the visit longer. Exact electrical settings and seizure adequacy depend on individual seizure threshold and specialist protocol.
Waking, recovery and discharge
People commonly wake with temporary confusion or fatigue and may notice a headache, nausea or muscle soreness. They recover under observation before leaving a clinical unit or returning to an inpatient ward. Outpatient care generally requires a responsible escort and avoidance of driving or other activities affected by anesthesia according to local instructions. Recovery time varies, and discharge should follow clinical readiness rather than a fixed clock. NIMH.
Between sessions
Staff should ask about mood, sleep, physical symptoms, disorientation and memory. Improvements may emerge gradually across a course. New cognitive problems, reduced ability to care for oneself or significant medical changes require timely reassessment. A typical schedule should remain flexible when adverse effects or inadequate response alter the balance of benefits and risks.
VI. ECT Side Effects and Safety
Common short-term effects
Headache, nausea, muscle soreness, temporary disorientation and fatigue are common adverse effects. Some resolve soon after waking, while cognitive symptoms may extend into the course of treatment. Side effects vary with procedure settings, patient characteristics and anesthesia. Clinicians can often provide symptomatic treatment or adjust parameters. NIMH.
Anesthesia and cardiovascular risks
ECT briefly changes autonomic nervous system activity and can increase or decrease heart rate and blood pressure at different stages of the procedure. General anesthesia carries respiratory, cardiovascular and medication-related risks. People with cardiovascular illness, recent neurologic events or other substantial medical complexity require particularly careful specialist assessment. Appropriate monitoring reduces preventable risk but cannot remove all possibility of complications. NICE.
Transient confusion versus autobiographical memory loss
The phrase 'memory loss' includes several distinct outcomes: temporary disorientation after anesthesia, difficulty retaining new material around treatment, and loss of recall for autobiographical experiences from a person's past. These effects differ in meaning, time course and how they are measured. A person may regain attention and ordinary learning while still having gaps in personal memories. Patients need a frank account of potential persistent loss rather than reassurance that every effect will resolve.
A 2025 online systematic review, appearing in the 2026 British Journal of Psychiatry, synthesized nine studies involving 432 ECT patients and 173 controls. ECT was associated with greater autobiographical memory loss than comparator conditions (standardized mean difference 0.55). The reported effect was larger for bilateral ECT (0.82) than right-unilateral ECT (0.32). Loss could persist at longer follow-up in available data, although study quality and design limit individual prediction. Mathiassen et al., systematic review.
Why memory reports and test scores differ
A systematic review published online in September 2026 examined twelve studies and 837 participants assessing both subjective and objective memory. Subjective memory ratings tended to improve after ECT, plausibly reflecting improvement in depression, while some objective memory outcomes—especially autobiographical recall—declined. Substantial heterogeneity remained. This helps explain why a person can feel mentally clearer yet experience lasting gaps in personal history. Both kinds of outcome matter. Verspecht et al., 2026.
Can technique reduce cognitive risk?
Electrode placement and pulse duration influence cognition. Right-unilateral ECT generally poses a lower autobiographical memory burden than bilateral ECT, but particular right-unilateral ultrabrief methods may have lower aggregate antidepressant effectiveness, requiring a change in technique. That tradeoff must be discussed explicitly. A cognitive-sparing protocol is a reasonable consideration, not a guarantee against memory loss or a substitute for tracking clinical response. Mathiassen et al.; Jelovac and McLoughlin; Sackeim et al..
Does ECT cause brain damage?
Current evidence does not establish that correctly delivered modern ECT causes the gross structural brain injury sometimes portrayed in popular culture. The clinical procedure is specifically designed and monitored to manage the seizure and minimize harm. At the same time, demonstrated memory impairments are real adverse effects with consequences for identity, relationships, study and work. Explaining the absence of established gross structural damage must never be used to dismiss a patient's cognitive experience. NIMH; autobiographical-memory meta-analysis.
When should an ECT course be stopped?
NICE recommends stopping ECT when stable remission has been achieved or immediately when adverse effects outweigh possible benefits. Before each continued session, the team should reassess whether likely improvement justifies further anesthesia, cognitive burden and other risks. Patients should have an accessible route to report significant side effects or change their decision. NICE 1.13.8.
VII. Informed Consent, Capacity and Rights
A valid informed decision requires an understandable discussion of diagnosis, treatment rationale, alternatives, likelihood and speed of benefit, serious risks, potential cognitive effects, and what may happen if ECT is postponed. The person should be able to ask questions, discuss past adverse experiences, involve a trusted supporter and receive time appropriate to clinical urgency. Written material is useful, but consent must be an actual exchange rather than a signed form alone. NICE consent recommendations.
Decision-making capacity is specific to the particular decision and may change with illness and recovery. Severe psychosis, catatonia or life-threatening illness can complicate assessment. Rules for substituted consent, advance directives, judicial authorization and emergency treatment differ by U.S. state and country. The applicable law and patient's documented preferences must be reviewed by the treating institution. The UK-specific legal provisions of NICE cannot be assumed to govern care in the United States.
Patients with capacity should be free to decline or withdraw consent in accordance with applicable law. A person who prioritizes preserving autobiographical memory may reasonably evaluate alternatives differently from someone seeking rapid relief from a dangerous episode. Their priorities are clinical inputs to shared decision-making, and consent should be revisited as treatment effects become clearer.
VIII. ECT in Older Adults, Adolescents and Complex Conditions
Older adults
Older adults can benefit substantially from ECT, especially when severe depression compromises nutrition, mobility or medical stability, or when medicines have problematic adverse effects. They may also carry additional anesthesia, cardiovascular or cognitive risk. Baseline memory, possible neurocognitive disorder, medications, frailty and physical health therefore require individualized assessment. Age is a consideration for balancing risk and benefit rather than a stand-alone verdict. NICE.
Children and adolescents
For certain severe indications, the United States FDA classifies ECT devices as Class II for catatonia or severe major depressive episodes associated with major depressive or bipolar disorder in people age 13 years and older who are treatment-resistant or need a rapid response. Regulatory classification describes the device's authorized framework and does not make ECT a routine treatment for adolescent sadness or uncomplicated depression. Evidence in young populations is more limited, and decisions require specialist pediatric psychiatric and anesthesia assessment, legally appropriate consent and assent, and careful cognitive monitoring. FDA device classification QGH; NIMH.
Pregnancy and other medical situations
ECT has been considered in selected severe presentations during pregnancy, but the overall treatment decision requires specialist perinatal, obstetric, anesthesia and psychiatric assessment. Maternal illness and medical urgency must be weighed together with fetal and procedural considerations. The diagnosis and management of perinatal depression belong to the separate reproductive mental-health cluster; this article addresses the general principle that physiologic circumstances change the risk assessment.
IX. ECT Compared With Other Depression Treatments
Medication and evidence-based psychotherapy
Antidepressants and structured psychotherapy are central treatments for many depressive presentations, and combined care may be suitable. ECT has a distinct role when the depression is particularly severe, urgent or inadequately responsive to previous interventions. An effective acute ECT course still requires a continuing treatment and monitoring strategy. The broader choice among depression treatment depends on episode severity, preferences, previous response, access and tolerability. NICE.
Transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (rTMS) uses magnetic fields to influence brain activity, ordinarily without general anesthesia and without intentionally inducing a therapeutic seizure. It generally requires a different schedule and causes a different set of side effects. Both rTMS and ECT have clinical applications for depression, but rTMS studies in nonurgent treatment-resistant depression do not establish equivalence for catatonia, psychotic depression or life-threatening nutritional decline. NIMH; VA/DoD.
Intravenous ketamine and intranasal esketamine
Ketamine administered intravenously and intranasal esketamine are separate interventions, with different dosing, regulatory requirements, monitoring and adverse-effect profiles. They may be considered in selected treatment-resistant cases. Their evidence cannot automatically be transferred to severe psychotic or catatonic depression or to patients requiring a particular rapid medical outcome. NIMH.
In the randomized U.S. ELEKT-D trial of adults with nonpsychotic treatment-resistant major depression, intravenous ketamine satisfied the prespecified noninferiority criterion compared with ECT on the trial's self-rated response outcome: 55.4% versus 41.2% responded. This trial addressed a particular population and specific protocols; it did not demonstrate that ketamine is universally more effective or safer than ECT. A separate five-trial meta-analysis suggested ECT advantages on some outcomes but was limited by small studies and risk of bias. Anand et al., NEJM 2023; Menon et al., JAMA Psychiatry 2023.
Choosing among options
An individualized comparison asks how dangerous the current episode is, what has already been adequately tried, which outcomes matter most, whether anesthesia is suitable, how distressing memory effects might be, how quickly improvement is needed, and what follow-up support is available. The presence of severe depressive symptoms alone does not make every intervention appropriate. Specialist reassessment is often the most valuable next step.
X. What Happens After Acute ECT?
Why relapse prevention is essential
ECT can produce substantial acute improvement, yet depressive symptoms may recur after an apparently successful course. Ending procedures without planning the next stage leaves the patient vulnerable to relapse. NICE recommends starting or continuing antidepressant medication or an appropriate psychological intervention after a beneficial ECT course and considering additional indicated treatment. This plan should be settled before discharge or the end of acute treatment. NICE 1.13.9.
Continuation and maintenance ECT
Continuation ECT means spaced treatments in the period immediately after acute improvement to reduce early relapse. Maintenance ECT typically describes longer-term intermittent treatment for patients with recurrent or persistent vulnerability. The schedule is individualized and may range from weekly visits to treatments separated by months. Each extension warrants renewed discussion of symptom benefit, cognitive adverse effects, anesthesia exposure and alternatives. NIMH.
What recent relapse studies show
A 2025 systematic review and meta-analysis of four randomized trials (254 participants) found that continuation ECT combined with pharmacotherapy reduced six-month relapse relative to pharmacotherapy alone: relative risk 0.57 (95% CI 0.37–0.88). The trials included participants with unipolar and bipolar depression and were relatively small, so this should support individualized shared decisions rather than a universal maintenance prescription. Jelovac et al., 2025.
Earlier randomized research also demonstrated that sustained treatment matters after ECT response. A practical follow-up plan includes medication review, scheduled appointments, depression symptom and function monitoring, sleep and nutrition support, access to urgent assessment, and a clear explanation of who to contact if symptoms return. Personal memory difficulties may require their own support and follow-up. Sackeim et al., JAMA 2001.
XI. What If ECT Does Not Help?
Inadequate response calls for a thoughtful review of diagnosis, severity, electrode configuration, stimulus dose, pulse width, number and spacing of sessions, medication interactions and expectations. Sometimes a different ECT technique may be considered; in other circumstances stopping ECT and selecting another treatment is the better decision. A negative response is information about treatment effectiveness in that episode, not evidence of a patient's personal failure.
If ECT previously produced little benefit, NICE recommends considering a repeat trial only after reviewing the adequacy of the first course, all other options and a patient-specific risk-benefit discussion. Significant cognitive harms, including persistent autobiographical memory gaps, require direct consideration before further procedures. NICE 1.13.5.
The clinician should reassess any new agitation, elevated or irritable mood, reduced need for sleep, unusual energy or other changes that might indicate bipolarity, mixed features, medical causes or treatment-associated effects. Correct classification has consequences for subsequent care.
XII. Questions to Ask Before Consenting to ECT
Ask the psychiatrist which specific clinical features make ECT appropriate now, which adequate treatments have been tried, why the planned technique was chosen, and how treatment success and unacceptable adverse effects will be measured. Ask what outcomes are expected for someone with your presentation rather than relying on a generic response percentage.
Discuss electrode placement, stimulus pulse width, the tradeoff between cognitive effects and antidepressant response, and the clinic's approach to documenting both subjective and objective memory change. Ask directly whether personal memories may be permanently affected and which types of memory complaints require urgent review. Mathiassen et al..
Ask how anesthesia risk is evaluated; who will be present during the procedure; how many sessions are initially planned; what would lead to a change of course; how transportation, driving and recovery work; and which costs or insurance requirements apply locally. Ask whether the proposed care is inpatient or outpatient.
Finally, discuss legal consent rights, support from a trusted person, any advance preferences, how to contact the team between sessions, and the continuation strategy if the acute course helps. Good care is measured by informed decisions and a safe follow-up process as well as acute symptom improvement.
XIII. Frequently Asked Questions
Is ECT painful?
The electrical stimulus is administered under general anesthesia, so the person is unconscious during treatment. Headache, muscle soreness or nausea may occur after waking and can be assessed and treated. NIMH.
Is ECT only a last resort?
ECT often follows unsuccessful prior treatment, but it may be considered earlier when severe depression causes immediate medical danger, psychotic features, catatonia or other urgent conditions. Choice is based on individual need, evidence and informed preference. NICE; VA/DoD.
How many ECT sessions are usual?
A common acute course involves six to twelve treatments, often three per week. Frequency and total sessions change with response, treatment settings and adverse effects. NIMH.
Can ECT permanently affect memories?
Yes. Some individuals experience persistent deficits in autobiographical memory, including memories of personal events. The severity and duration vary, and right-unilateral treatment tends to carry lower risk than bilateral approaches in available studies. Mathiassen et al..
Does ECT cure depression permanently?
ECT can achieve acute remission but does not ensure permanent protection against new episodes. Ongoing psychiatric care, medication or psychotherapy and, for selected people, continuation or maintenance ECT may help prevent relapse. Jelovac et al..
Is ECT the same as transcranial magnetic stimulation?
No. ECT involves general anesthesia and an intentionally induced seizure. TMS usually uses magnetic pulses while the person is awake and does not deliberately induce a seizure. The methods have different efficacy data, risks and indications. NIMH.
Can teenagers receive ECT?
Under the relevant U.S. FDA device classification, certain severe treatment-resistant or urgent indications are included for people age 13 and older. Pediatric treatment requires particularly careful specialist assessment, consent and legal safeguards; age eligibility is not a routine treatment recommendation. FDA.
What about ECT and anxiety or OCD?
Anxiety and obsessive-compulsive symptoms can coexist with depression, but do not independently determine an ECT indication. Clinical assessment should consider the whole presentation. Relevant separate articles cover anxiety and depression and OCD and depression.
What if someone has a trauma history?
Trauma-related experiences may shape trust, procedural anxiety, perceived control and the personal meaning of memory changes. These experiences deserve respectful, individualized discussion and consent practices. Trauma history itself does not determine whether ECT is indicated. See the separate article about childhood trauma and depression.
When is urgent help needed?
If severe depression prevents eating or drinking, causes marked unresponsiveness, involves dangerous psychotic symptoms or creates imminent suicidal risk, seek urgent in-person assessment. In the United States call 911 for immediate danger or 988 for suicidal crisis support. Elsewhere use local emergency services. Emergency evaluation determines immediate safety and medical needs; it does not automatically determine an ECT indication.
XIV. Evidence Limitations and Clinical Conclusion
ECT has a substantial evidence base for selected severe depressive episodes, but clinical estimates depend on the particular technique, trial population and outcome. Some contemporary comparisons are limited by unblinded treatment, heterogeneous protocols, small samples or exclusions of severe psychotic illness. A result in nonpsychotic treatment-resistant depression cannot automatically guide an emergency decision for catatonia. The strongest clinical practice combines high-quality evidence with comprehensive assessment and patient preferences.
ECT can provide powerful and sometimes rapid relief from severe depressive illness. It also carries real medical and cognitive risks, including possible persistent loss of autobiographical memories. The responsible decision therefore integrates psychiatric and anesthesia assessments, a clear account of alternatives, voluntary informed consent when capacity is present, careful technique choice, monitoring of both mood and cognition, and a plan for sustained care. NICE; NIMH; Mathiassen et al..
This article provides educational information and does not establish a diagnosis or replace individualized medical advice from a qualified psychiatric and anesthesia team.
Related Articles
References
Anand, A., et al. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine, 388, 2315–2325. https://doi.org/10.1056/NEJMoa2302399.
Food and Drug Administration. (2018; classification accessed 2026). Electroconvulsive therapy device for catatonia, major depressive disorder, and bipolar disorder. FDA product code QGH, Class II. FDA classification.
Jelovac, A., Braithwaite, R., Kellner, C. H., & McLoughlin, D. M. (2025). Continuation electroconvulsive therapy combined with pharmacotherapy for depression relapse prevention: A systematic review and meta-analysis. Psychological Medicine, 55, e251. https://doi.org/10.1017/S0033291725101608.
Jelovac, A., & McLoughlin, D. M. (2026; online 2025). Ultrabrief pulse electroconvulsive therapy for depression: A systematic review and meta-analysis. Molecular Psychiatry, 31, 1132–1141. https://doi.org/10.1038/s41380-025-03327-z.
Mathiassen, A. B., Semkovska, M., Lundsgaard, C. C., Gbyl, K., & Videbech, P. (2026; online 2025). Autobiographical memory after electroconvulsive therapy: Systematic review and meta-analysis. British Journal of Psychiatry, 228, 263–273. https://doi.org/10.1192/bjp.2025.2.
Menon, V., Varadharajan, N., Faheem, A., & Andrade, C. (2023). Ketamine vs electroconvulsive therapy for major depressive episode: A systematic review and meta-analysis. JAMA Psychiatry, 80, 639–642. https://doi.org/10.1001/jamapsychiatry.2023.0562.
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222), section 1.13. NICE official guideline.
National Institute of Mental Health. (n.d.). Brain stimulation therapies: Electroconvulsive therapy. NIMH official resource.
Sackeim, H. A., et al. (2001). Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: A randomized controlled trial. JAMA, 285, 1299–1307. https://doi.org/10.1001/jama.285.10.1299.
Sackeim, H. A., et al. (2008). Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimulation. PubMed PMID 19756236.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2022). VA/DoD clinical practice guideline for the management of major depressive disorder. VA/DoD official guideline.
Verspecht, S., et al. (2026). Subjective and objective memory effects after electroconvulsive therapy for depressive disorders: Systematic review and meta-analysis. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2026.09.018.